89bio (ETNB) Stock Price, News & Analysis

-0.30 (-3.36%)
(As of 02:20 PM ET)
Today's Range
50-Day Range
52-Week Range
346,102 shs
Average Volume
1.22 million shs
Market Capitalization
$820.80 million
P/E Ratio
Dividend Yield
Price Target

89bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
231.4% Upside
$29.00 Price Target
Short Interest
12.13% of Shares Sold Short
Dividend Strength
News Sentiment
0.43mentions of 89bio in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$20.72 M Bought Last Quarter
Proj. Earnings Growth
From ($2.20) to ($2.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.94 out of 5 stars

Medical Sector

575th out of 909 stocks

Pharmaceutical Preparations Industry

258th out of 423 stocks

ETNB stock logo

About 89bio Stock (NASDAQ:ETNB)

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

ETNB Stock Price History

ETNB Stock News Headlines

89bio (NASDAQ:ETNB) Receives "Buy" Rating from Bank of America
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Reviewing 89bio (NASDAQ:ETNB) & 2seventy bio (NASDAQ:TSVT)
89bio Inc CEO Rohan Palekar Sells 52,718 Shares
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
ETNB Apr 2024 12.500 put
89bio price target raised by $8 at Evercore ISI, here's why
89bio Inc.
ETNB Mar 2024 20.000 put
ETNB Mar 2024 20.000 call
89bio Inc
ETNB Mar 2024 15.000 call
See More Headlines
Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$5.75 per share


Free Float
Market Cap
$849.36 million
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Rohan PalekarMr. Rohan Palekar (Age 58)
    CEO & Director
    Comp: $990.52k
  • Mr. Quoc Le-Nguyen (Age 56)
    Chief Technical Operations Officer & Head of Quality
    Comp: $654.44k
  • Dr. Harry Mansbach M.D. (Age 59)
    Chief Medical Officer
    Comp: $691.87k
  • Mr. Ryan Stephen Martins (Age 45)
    Chief Financial Officer
  • Mr. Shiva K. Natarajan CPA (Age 58)
    Senior Vice President of Finance & Principal Accounting Officer
  • Ms. Annie J. Chang M.B.A.
    VP of Investor Relations & Corporate Communications
  • Ms. Amanda Kurihara
    Vice President of People & Culture
  • Ms. Yun Bai Ph.D.
    VP and Head of Chemistry, Manufacturing & Controls ( CMC )
  • Ms. Melissa Abel
    Senior Vice President of Commercial Strategy
  • Mr. Paul Shin
    Senior Vice President of R&D Operations

ETNB Stock Analysis - Frequently Asked Questions

Should I buy or sell 89bio stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ETNB shares.
View ETNB analyst ratings
or view top-rated stocks.

What is 89bio's stock price target for 2024?

7 analysts have issued 12-month price targets for 89bio's stock. Their ETNB share price targets range from $14.00 to $37.00. On average, they expect the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 231.4% from the stock's current price.
View analysts price targets for ETNB
or view top-rated stocks among Wall Street analysts.

How have ETNB shares performed in 2024?

89bio's stock was trading at $11.17 at the beginning of 2024. Since then, ETNB stock has decreased by 21.7% and is now trading at $8.75.
View the best growth stocks for 2024 here

When is 89bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ETNB earnings forecast

How were 89bio's earnings last quarter?

89bio, Inc. (NASDAQ:ETNB) posted its earnings results on Thursday, February, 29th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.01.

What ETFs hold 89bio's stock?

ETFs with the largest weight of 89bio (NASDAQ:ETNB) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC).Harbor Health Care ETF (MEDI).

What other stocks do shareholders of 89bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

When did 89bio IPO?

89bio (ETNB) raised $70 million in an initial public offering on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Who are 89bio's major shareholders?

89bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Raymond James Financial Services Advisors Inc. (0.12%), Bourgeon Capital Management LLC (0.04%) and Wetzel Investment Advisors Inc. (0.01%). Insiders that own company stock include Edward Morrow Atkinson III, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends

How do I buy shares of 89bio?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ETNB) was last updated on 4/24/2024 by Staff

From Our Partners